These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 23718922)

  • 41. Activated partial thromboplastin time as a screening test of minor or moderate coagulation factor deficiencies for canine plasma: sensitivity of different commercial reagents.
    Mischke R
    J Vet Diagn Invest; 2000 Sep; 12(5):433-7. PubMed ID: 11021430
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Lyophilized plasmas for the control of thromboplastin time values and calibration of thromboplastins].
    Sikorová J; Vorlová Z
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1987; 114(3):423-8. PubMed ID: 2444517
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples.
    Hapgood G; Butler J; Malan E; Chunilal S; Tran H
    Thromb Haemost; 2013 Aug; 110(2):308-15. PubMed ID: 23783268
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Effect of reagent batch on activated partial thromboplastin time in canine plasma and use of the ratio system for standardization].
    Mischke R
    Berl Munch Tierarztl Wochenschr; 2002; 115(5-6):225-9. PubMed ID: 12058600
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A combined approach using global coagulation assays quickly differentiates coagulation disorders with prolonged aPTT and low levels of FVIII activity.
    Matsumoto T; Nogami K; Shima M
    Int J Hematol; 2017 Feb; 105(2):174-183. PubMed ID: 27730530
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of the activated partial thromboplastin time assay for clinical monitoring of PEGylated recombinant factor VIII (BAY 94-9027) for haemophilia A.
    Gu JM; Ramsey P; Evans V; Tang L; Apeler H; Leong L; Murphy JE; Laux V; Myles T
    Haemophilia; 2014 Jul; 20(4):593-600. PubMed ID: 24471985
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of the Q analyzer, a new cap-piercing fully automated coagulometer with clotting, chromogenic, and immunoturbidometric capability.
    Kitchen S; Woolley A
    Blood Coagul Fibrinolysis; 2013 Jan; 24(1):28-34. PubMed ID: 23249565
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Chromogenic substrates for activated partial thromboplastin time testing: are they worth using?
    Tripodi A
    Ric Clin Lab; 1989; 19(4):355-8. PubMed ID: 2517351
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The investigation of a prolonged APTT with specific clotting factor assays is unnecessary if an APTT with Actin FS is normal.
    Bowyer A; Smith J; Woolley AM; Kitchen S; Hampton KK; Maclean RM; VAN Veen JJ; Makris M
    Int J Lab Hematol; 2011 Apr; 33(2):212-8. PubMed ID: 20880301
    [TBL] [Abstract][Full Text] [Related]  

  • 50. New guidelines for lupus anticoagulant: sensitivity and specificity of cut-off values calculated with plasmas from healthy controls in mixing and confirmatory tests.
    Martinuzzo ME; Cerrato GS; Varela ML; Adamczuk YP; Forastiero RR
    Int J Lab Hematol; 2012 Apr; 34(2):208-13. PubMed ID: 22032515
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Analysis of APTT Mixing Test Results in Factor Ⅷ Inhibitor-Positive Hemophilia Patients].
    Zhang LH; Xie ZQ; Zhuang H; Wang MH; Cao YP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1791-1796. PubMed ID: 38071062
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The impact of oral anticoagulant therapy, factor VIII level and quality of factor V-deficient plasma on three commercial methods for activated protein C resistance.
    Chitolie A; Lawrie AS; Mackie IJ; Harrison P; Machin SJ
    Blood Coagul Fibrinolysis; 2001 Apr; 12(3):179-86. PubMed ID: 11414631
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparative effects of the human protein C activator, Protac, on the activated partial thromboplastin clotting times of plasmas, with special reference to the dog.
    Johnstone IB; Martin CA
    Can J Vet Res; 2000 Apr; 64(2):117-22. PubMed ID: 10805251
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Automated amidolytic method for evaluating the activated partial thromboplastin time compared with a conventional coagulation method.
    Tripodi A; Poggio M; Scapellato L; Mannucci PM
    Haemostasis; 1989; 19(4):205-12. PubMed ID: 2509308
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The dilute phospholipid APTT: a sensitive assay for verification of lupus anticoagulants.
    Alving BM; Baldwin PE; Richards RL; Jackson BJ
    Thromb Haemost; 1985 Oct; 54(3):709-12. PubMed ID: 3937268
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Applicability of activated partial thromboplastin time (APTT) as a screening test of milk to medium deficiencies of coagulation factors in cats].
    Deniz A; Mischke R; Nolte I
    Dtsch Tierarztl Wochenschr; 1995 May; 102(5):206-8. PubMed ID: 8593777
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Assignment of international normalized ratio to frozen and freeze-dried pooled plasmas.
    van den Besselaar AMHP; Cobbaert CM
    Clin Chem Lab Med; 2020 Nov; 58(12):2089-2097. PubMed ID: 32840098
    [TBL] [Abstract][Full Text] [Related]  

  • 58. An Analysis of the Sensitivity of the Activated Partial Thromboplastin Time (APTT) Assay, as Used in a Large Laboratory Network, to Coagulation Factor Deficiencies.
    Do L; Favaloro E; Pasalic L
    Am J Clin Pathol; 2022 Jul; 158(1):132-141. PubMed ID: 35150232
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Reflex factor coagulation testing in patients with an unexplained prolonged aPTT: An institutional retrospective review.
    Mansory EM; Bahodi F; Phua CW
    Int J Lab Hematol; 2022 Feb; 44(1):202-208. PubMed ID: 34623751
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Activated partial thromboplastin time. Evaluation of sensitivity and validity for determination of factor VIII coagulant activity].
    Camici M; Evangelisti L
    Minerva Med; 1993 Feb; 84(1-2):11-6. PubMed ID: 8464562
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.